Venture capital (VC) funding for the Life Sciences sector, which includes Biotechnology and Medical Devices, reached $2.5 billion in 195 deals for the second quarter of 2014, according to a new report, “Biotech soars to record high,” which includes data from the MoneyTree™ Report from PricewaterhouseCoopers (PwC) LLP and the National Venture Capital Association (NVCA), based on data provided by Thomson Reuters. While this quarter was the highest Life Sciences investment since the second quarter 2007, it was also the strongest second quarter since 1995, which is the earliest data recorded by the MoneyTree.
{iframe}http://www.marketwatch.com/story/life-sciences-venture-capital-investments-soar-in-q2-to-highest-level-since-2007-according-to-the-moneytree-report-2014-08-25{/iframe}